Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by eric40on Aug 10, 2017 9:53am
325 Views
Post# 26565306

RE:Is the FDA onsite doing the inspection yet?

RE:Is the FDA onsite doing the inspection yet? The FDA visit to Laval facility is sceduled mid august. It is a re-certification because of an update on the water filtration process (from what I heard). Any modification in an already FDA approuved facility has to be reapproved.

The shorts takes advantage of the down momentum they have very succesfully created over the last 8-9 months. CIBC was not invited in the last financing (or the canadian madatory part of the Cantor deal) because of there shorting activity on PLI prior to the cantor deal. So they continued shorting.

PLI is cut in a downfall crisis spiral , help by the shorts, the bad mood of pharma  market in Canada and obviously because Prometic is still slow in delivering, creating a lack of credibility with small investor.

The science is good, big investor are still in, science is progressing and in some weeks or months there will be a BLA for PG and the start of revenu for Prometic.

This should help the credibility to come back.

The managment has to deliver and control the cash position and cash burns and then SP should recover 



Bullboard Posts